Over the last 18 months, the Journal has published several reports and letters to the editor describing cases where the use of sugammadex to reverse rocuronium-induced neuromuscular block improved patient management and possibly outcome. These cases have fallen into three broad categories. First, the use of rocuronium with pre-planned early reversal by sugammadex as a strategy to provide a short duration of neuromuscular block in situations where the traditional choice, succinylcholine, is relatively contraindicated. For example, Eissa and Kim reported the successful use of this strategy in a patient with plasmacholinestrease deficiency presenting for electroconvulsive therapy 1 . Visser et al reported similar success in a patient with atypical cholinesterase 2 . Saeki et al reported the successful use of this strategy in a patient with neurolept malignant syndrome requiring electroconvulsive therapy 3 . The second category is the use of rocuronium and the pre-planned reversal by sugammadex instead of neostigmine as a strategy to provide rapid and complete reversal of non-depolarising neuromuscular block in situations where even subclinical residual neuromuscular block may be harmful. For example, Porter and Paleologos reported the successful use of this strategy in a patient with endstage lung disease secondary to cystic fibrosis who required a percutaneous endoscopic gastrostomy 4 . Similarly, Baumgartner and later Petrovski reported the successful use of this strategy in patients with myotonic dystrophy 5, 6 . This category would extend to patients in whom reversal with anticholinesterases may be only partially effective (e.g. patients with poor renal function, hypothermia, acidosis), especially if they had required deep levels of neuromuscular block late into the procedure (e.g. laparotomies).
The third category is the unplanned early reversal of rocuronium by sugammadex in patients who have an unexpected difficult intubation, and would be best awakened and considered for an awake fibreoptic intubation or other technique. For example, DesForges and McDonnell reported the effective and possibly life-saving use of this strategy in the management of a failed intubation in a morbidly obese patient 7 . McTernan et al previously described the benefit of having an option for early reversal of neuromuscular block in a case of anticipated difficult intubation 8 . Despite the absence of randomised controlled trials confirming the superiority of rocuronium (or other aminosteroid neuromuscular blocking drug) and sugammadex in these situations, few anaesthetists would argue that the ability of sugammadex to rapidly and completely reverse even deep levels of rocuronium neuromuscular block [9] [10] [11] [12] would not make this combination an ideal choice for the three categories mentioned. Moreover, this assessment would be made independent of the current high price of sugammadex, on the basis that this is a relatively small additional cost for the likely benefit obtained.
However, there are other potential indications for rocuronium/sugammadex combinations for which more compelling evidence of benefit would be required. For example, the use of sugammadex as an alternative to neostigmine solely to reduce surgical or anaesthetic time (without any other indication) would require a clear demonstration of a reduction in these times 13, 14 . More importantly, the routine use of sugammadex as an alternative to neostigmine in order to reduce complications associated with residual neuromuscular block or even the adverse effects of neostigmine (plus antimuscarinic agent) would require a clear demonstration of a reduction in these complications 13,14. Ideally, such demonstrations would require randomised controlled trials of rocuronium-sugammadex vs rocuronium-neostigmine. Unfortunately, in contrast to the numerous studies demonstrating the superiority of sugammadex for reversing rocuronium [9] [10] [11] [12] , there have been no trials examining the effect of the routine use of sugammadex on either perioperative times or complications.
In this issue of the Journal, there are two audits of the use of sugammadex before and after removal of a hospital restriction on its use 15, 16 . The removal of the restrictions were made possible by price negotiations between the hospital and the manufacturer, prior to which sugammadex was used only for specific and very limited indications. The details of these negotiations are confidential but required making sugammadex available for all cases in which rocuronium or vecuronium were used, and indicating to the anaesthetists involved that price was no longer a consideration. Therefore, these audits give us some indication of the likely pattern of sugammadex use if price considerations are removed. Predictably, there was a substantial increase in the use of sugammadex in both audits. However, as the authors have indicated, we have to be circumspect in interpreting the magnitude of the increase, because it may have been influenced to some extent by curiosity, novelty, or the opportunity to obtain clinical experience with this relatively new and otherwise expensive drug without cost implications. Moreover, there may have been some subtle imperatives to use a certain amount of sugammadex in order to fulfil the conditions of the price reductions.
Irrespective of the cause, the increased use of sugammadex gives us an opportunity to observe the effect, if any, of this on anaesthesia times, durations of post-anaesthesia care unit stay, and length of hospital stay. From the outset we have to be cautious, because both audits were retrospective and neither were powered to assess these endpoints. As it happens, the audits had somewhat conflicting findings. Watts et al observed a reduction in anaesthesia time (induction to transfer to postanaesthesia care unit) from a mean of 143.5 minutes to a mean of 120 minutes but they had a larger of number of laparoscopies vs laparotomies in their high use sugammadex group 15 . Moreover, they did not have access to the case notes of between 8 and 9% of their cases. Their claim that the difference in anaesthesia times remained significant after adjustment for confounding variables has to be interpreted in the light of the limited power to accurately adjust for such variables in this type of audit. In contrast, Ledowski et al observed no significant difference in surgical times or anaesthesia times in their high use sugammadex group 16 and neither of the audits observed a significant reduction in post-anaesthesia care unit times.
In relation to length of stay, Watts et al observed a significant reduction from 4.3 days with restricted sugammadex to 3.4 days with unrestricted sugammadex 15 . However, this difference was no longer significant when adjusted for confounding variables (e.g. casemix). Nevertheless, as indicated above, it would be extremely difficult to accurately adjust for all confounding variables. Therefore, a true reduction cannot be excluded. Ledowski et al also observed a small, but significant reduction in length of stay (mean 78 hours in the restricted sugammadex group vs 73 hours in the unrestricted group) 16 . Most of this difference occurred after the end of surgery; i.e. time from end of surgery to discharge (mean of 2.2 vs 2.0 days). Ledowski et al did not adjust for confounding variables, but had similar casemix for both groups. They indicated that 'it would be interesting to speculate' that the observed reduction was due to decreased complications in the unrestricted sugammadex use group, but also indicated that the 12-month gap between the two groups would make it difficult to exclude a change in hospital policy or culture toward earlier discharge as an explanation for the difference.
Despite their many acknowledged limitations, and the declared conflicts of interest, both audits present observations that might be important and they are therefore valuable contributions to our knowledge about this new drug. These observations include both the apparent absence of adverse effects attributable to sugammadex and the possibility of a reduction in anaesthesia times and even length of stay when sugammadex use is increased.
Incidentally, also in this issue, Kyle et al report the failure of successful early reversal of rocuronium by sugammadex to improve a 'can't intubate, can't oxygenate' crisis 17 , indicating that the return of normal motor strength will not always improve the situation. Bisschops et al reported that substantial delay encountered in the preparation and administration of sugammadex could be fatal in a simulated 'cannot intubate, cannot ventilate' situation 18 . More studies on the role of sugammadex in this clinical situation are needed and anaesthetists should not with a false sense of security violate current recommendations for the management of a patient with a difficult airway 19 . Clearly, we require further studies to confirm the safety and define the eventual role of sugammadex in anaesthesia practice. Allergy to sugammadex has been reported 20 and further studies evaluating the potential for hypersensitivity (especially for repeat administrations) and drug interactions with sugammadex are required 21 . In the meantime, there appears to be sufficient rationale already for its selective use for specific indications, whether planned or unplanned. Importantly, these indications are likely to expand, as suggested in other published correspondence 22, 23 . For this reason, anaesthetists should not be restricted in their access to sugammadex. Whether sugammadex becomes the reversal agent of choice non-selectively will depend on its eventual market price, the outcome of future trials, and further experience with its use.
